Toddr Patrick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update Company earns $750,000 milestone payment related to SWARM-P.a. Study News provided by Share this article Share this article MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided a corporate update.   First Quarter 2021 and Recent Highlights: Continued to advance the single ascending dose (SAD) cohort of the SWARM- P.a. Phase 1b/2a clinical trial evaluating AP-PA02 as a potential treatment for cystic fibrosis patients with chronic

United statesToddr patrickJoyce allaireSteve martinUs department of defenseLifesci advisorsDefense health agencyArmata pharmaceuticals incWarfighter medical research programTherapeutics development awardCf foundationInnoviva incCystic fibrosis cf foundationInnoviva strategic opportunitiesTechnology enterprise consortiumPrnewswire armata pharmaceuticals inc